"Designing Growth Strategies is in our DNA"

Cardiac Biomarkers Market Size, Share & Industry Analysis, By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Others), By Biomarker (Troponin, Creatine kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP), Myoglobin, and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2020-2032

Last Updated: September 23, 2024 | Format: PDF | Report ID: FBI101233

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The global cardiac biomarkers market size was valued at USD 13.15 billion in 2019 and is projected to reach USD 48.26 billion by 2032, exhibiting a CAGR of 11.9% during the forecast period.


This type of biomarkers are certain endogenous substances including enzymes, hormones, and proteins, which are released into the blood during specific cardiovascular conditions indicating the abnormality of the cardiac functioning. Healthcare providers are now focusing on the detection of these specific markers, to identify and diagnose critical cardiac conditions, including myocardial infarction, heart attack, and acute coronary syndrome (ACS) or other conditions. Various tests have been developed by market players to accurately and timely detect the presence of these biomarkers, which have been instrumental in early diagnosis of cardiovascular conditions.


According to the World Heart Federation, Harvard University studies, along with other sources, individuals with pre-existing medical conditions, such as diabetes, heart disease, among others are more vulnerable to the novel coronavirus. Also, patients with pre-existing heart disease suffering from COVID-19 are more prone to high risks of heart attack or develop congestive heart failure. A more unusual condition called myocarditis has been observed in COVID-19 patients being admitted in emergency departments globally. Additionally, the National Health Commission (NHC) of China demonstrated that 35.0% of the total patients diagnosed with COVID-19 (sample size of 46,248) were suffering from hypertension and 17.0% were suffering from coronary heart disease. This has led to an increase in demand and adoption of cardiac biomarkers tests in patients suffering from COVID-19.


However, there has been a significant drop in the number of patients visiting in the emergency departments globally, during the current outbreak of COVID-19 pandemic. According to an article published by The New York Times, there has been 40.0% to 60.0% reduction in admissions in patients suffering from heart attack during March and April 2020. Additionally, various cardiologists in Spanish hospitals reported around 40.0% reduction in admissions of patients in emergency departments for conditions including strokes, and heart attacks. The significant decline in the number of patients admitted is anticipated to have significant decline in the number of cardiac biomarker tests performed which is projected to impact the global industry in 2020.


MARKET TRENDS


Request a Free sample to learn more about this report.


Adoption of Point-of-Care Biomarker Tests to Boost Market Growth


Rising prevalence of cardiovascular disorders is one of the major factors expected to increase the demand for rapid and POC cardiac biomarkers testing. Key market players are investing in the development of rapid biomarker test kits hence expected to drive the market growth. The point care test offers clinical benefits including reduced diagnosis time in comparison to the traditional laboratory-based tests. For instance, in March 2017, F. Hoffmann-La Roche AG received FDA clearance to Elecsys Troponin T (TnT) Gen 5 Stat blood test for diagnosis of myocardial infarction. The test provides results in 9 minutes, shortening the time to diagnosis by almost 3 hours when compared with Roche’s conventional TnT test. There is a gradual shift in the adoption of rapid POC tests for detection of this type of biomarkers in emerging and developed countries.


MARKET DRIVERS


Rising Prevalence of Cardiovascular Diseases to Drive the Market


The burden of cardiovascular diseases (CVDs) is rising globally, owing to numerous factors such as smoking, diabetes, obesity, and lifestyle changes. According to the National Centre for Health Statistics, coronary artery diseases (CAD) account for 1 in 4 deaths in the U.S. annually. According to, Centers for Disease Control and Prevention, around 1.5 million cases of myocardial infarctions are registered annually in the United States. Additionally, according to Patient Platform Limited, around 103,000 people in the United Kingdom suffer from myocardial infarction each year. Rising prevalence of cardiovascular disorders is one the major factor anticipated to drive the market growth during the forecast period.


Additionally, according to the current scenario of 2020, coronavirus disease 2019 (COVID-19) has affected more than 129 countries globally. The impact of COVID-19 on patients suffering from cardiovascular disorder is high and patients suffering from COVID-19 are anticipated to trigger certain cardiovascular disorders such as heart failure, acute coronary syndrome, and among others. According to an article published by NCBI in March 2020, states that although COVID-19 affects the respiratory tract and other related organs, it has a huge impact on cardiovascular disorders. Additionally, according to various studies from China including 1,527 patients with COVID-19, 16.4% reported co-morbid conditions. Out of this 9.7%, 16.4% and 17.1% of patients reported diabetes, cardio-cerebrovascular diseases, and hypertension respectively. This has laid down makeshift reforms and protocols, to test COVID-19 patients with biomarkers, and other tests in healthcare settings globally. These are some of the factors anticipated to trigger the use of biomarker testing globally, hence driving the market growth.


Introduction of Novel Biomarker Tests to Drive the Market


Robust research and development on cardiovascular interventions and the introduction of rapid and novel biomarker tests is anticipated to drive the market growth during the forecast period of 2020-2027. Key market players are investing in the research and development of novel biomarkers for the diagnosis, prognosis, and predictive analysis of cardiovascular disorders.


In July 2019, Siemens received the U.S. Food and Drug Administration (FDA) approval for high-sensitivity troponin I assays (TnIH) to aid early diagnosis of myocardial infarctions. Additionally, in September 2019, Abbott received U.S. Food and Drug Administration (FDA) approval for its ARCHITECT STAT High Sensitivity Troponin-I blood test. The test is designed to detect heart attacks in quick time, and more accurately than contemporary troponin tests. The introduction of such novel tests for detection of these biomarkers is anticipated to propel the demand for these tests, and subsequently drive the growth rate of the market during the forecast period.


MARKET RESTRAINT


Lack of Availability of POC Testing Kits and delayed Test Results Anticipated to Hamper the Market Growth


Despite the rising prevalence of cardiovascular disease and the use of this type of biomarkers for diagnosis and treatment, there are certain factors hindering the growth of the market. The time period required to obtain results from certain biomarker tests is relatively higher and lead to several further complications such as misdiagnosis. For instance, Increased CK-MB can usually be detected in a patient with a heart attack about 3-6 hours after the onset of chest pain. The duration of results for evaluating these conditions with the use of laboratory-based biomarkers tests is relatively high. This has limited the uptake of cardiac biomarkers for diagnosis of acute conditions, and has compelled healthcare providers towards alternative diagnostic methods.


SEGMENTATION


By Indication Analysis


To know how our report can help streamline your business, Speak to Analyst


Acute Coronary Syndrome Segment is anticipated to grow at faster pace during the forecast period


Based on indication, the cardiac biomarkers market is segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, and others. The acute coronary syndrome segment dominated the indication segment in 2019. Rising prevalence of the acute coronary syndrome is propelling demand for these biomarkers. This is one of the major factors anticipated to drive the growth of the segment in the market. The myocardial infarction is anticipated accounted to the second-largest share in 2019 and is anticipated to grow at a significant CAGR during the forecast period of 2020-2027.


By Biomarker Analysis


Troponin Dominated the Biomarker Segment


In terms of biomarkers, the market is segmented into troponin, creatine kinase, b-type natriuretic peptide (BNP), myoglobin, and others. The troponin segment is estimated to grow at a significant CAGR during the forecast period due to high preference among end-users. The troponin test is performed for the diagnosis of myocardial infarction, acute coronary syndrome, and among others. The rising prevalence of the myocardial infarction and acute coronary syndrome is one the major factor anticipated to propel the demand of the troponin test during the forecast period. Creatine Kinase segment is anticipated to grow at a significant CAGR during the forecast period of 2020-2027.


By End User Analysis


Higher Adoption of Cardiac Biomarkers by Hospitals to Enable Dominance of the Segment


Rising healthcare expenditure and the development of new hospitals in developing countries are some of the major factors attributable to the dominance of the hospitals segment. Increasing prevalence of cardiovascular disorders and COVID-19 is also one of the additional factors anticipated to propel the growth of the hospital segments. A rapidly developing hospital infrastructure in emerging countries, and clinical laboratories being an integral part of large hospitals, have been instrumental in higher adoption of cardiac biomarkers tests globally. These factors combined with adequate reimbursement policies for inpatient admissions in emerging countries are driving the growth of the hospitals segment in the market.


However, increasing specialty clinics and a number of ambulatory surgical centers in developed countries is anticipated to drive the growth of the specialty clinics at significant CAGR during the forecast period of 2020-2027.


REGIONAL ANALYSIS


North America Cardiac Biomarkers Market Size, 2016-2027 (USD Billion)

To get more information on the regional analysis of this market, Request a Free sample


The market size in North America stood at USD 5.23 billion in 2019. North America is expected to hold a major market share due to the rising prevalence of cardiovascular diseases. For instance, according to the American College of Cardiology Foundation an estimated 1.05 million patients were suffering from coronary disorders in the United States alone, in 2019. This is presenting a large pool requiring diagnostic procedures, fueling the demand for cardiac biomarkers in North America. Europe is anticipated to grow at a faster pace owing to due to rising prevalence of acute coronary syndrome and myocardial infarction leading to an increase in demand for these biomarkers. Asia Pacific, on the other hand, is anticipated to grow at a significant CAGR due to the introduction of technologically advanced cardiac biomarkers, and developing healthcare infrastructure leading to higher adoption of these tests in countries including China, and India. Latin America and Middle East & Africa are anticipated to grow at a moderate rate due to slower adoption of technologically advanced solutions and lack of awareness among the population towards tests for cardiac biomarkers.  


KEY INDUSTRY PLAYERS


F. Hoffmann-La Roche AG, Abbott and Siemens AG are some of the leading market players


The market is highly fragmented. In 2019, F. Hoffmann-La Roche AG, Abbott, and Siemens AG were among the top market players accounting for more than 30.0% share of the market. The competitive landscape consists of large, mid-size, and small companies that have developed different types of biomarkers to target various indications. Key market players are focused on achieving growth through the development of innovative product designs & new tests and inclined towards the specificity of the tests based on detection of cardiac biomarkers.


LIST OF KEY PLAYERS PROFILED:



  • F. Hoffmann-La Roche AG

  • Abbott

  • Siemens AG

  • Creative Diagnostics

  • Beckman Coulter, Inc.

  • Bio-Rad Laboratories, Inc.

  • Thermo Fisher Scientific Inc.

  • bioMérieux SA

  • Others


KEY INDUSTRY DEVELOPMENTS:



  • April 2021 – F. Hoffmann-La Roche Ltd announced the launch of five new applications for their key cardiac biomarkers in combination with their Elecsys technology. These biomarkers have been proved to be successful managing cardiovascular diseases and can help clinicians to diagnose heart attacks and manage heart failures in patients.

  • April 2021 –Siemens AG. announced that they received CE Mark approval for their point-of-care Atellica VTLiPatient-Side Immunoassay Analyzer, a high sensitivity troponin I test. The approved device detects protein biomarkers for acute myocardial infraction.


REPORT COVERAGE


An Infographic Representation of Cardiac Biomarkers Market

To get information on various segments, share your queries with us



The cardiac biomarkers market report provides a detailed analysis of the market and focuses on key aspects such as leading companies, biomarker types, and leading applications of the biomarkers. Besides this, the report offers insights into the market, current cardiac biomarkers market trends, the impact of COVID-19 on cardiovascular disorders and highlights the key industry developments. In addition, the report encompasses several factors that have contributed to the growth of the market over the recent years.


Report Scope & Segmentation











































 ATTRIBUTE



 DETAILS



Study Period



  2016-2027



Base Year



  2019



Forecast Period



  2020-2027



Historical Period



  2016-2018



Unit



  Value (USD billion)



Segmentation



By Indication



  • Myocardial Infarction

  • Congestive Heart Failure

  • Acute Coronary Syndrome

  • Others



By Biomarker



  • Troponin

  • Creatine Kinase-MB (CK-MB)

  • B-type Natriuretic Peptide (BNP)

  • Myoglobin

  • Others



By End User



  • Hospitals

  • Specialty Clinics



By Geography



  • North America (the U.S. and Canada)

  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)

  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)

  • Latin America (Brazil, Mexico, and the Rest of Latin America)

  • The Middle East & Africa (South Africa, GCC and the Rest of Middle East & Africa)






Frequently Asked Questions

Fortune Business Insights says that the global market size was USD 13.15 billion in 2019 and is projected to reach USD 26.33 billion by 2027.

In 2019, the market value stood at USD 13.15 billion.

Growing at a CAGR of 11.2%, the market will exhibit steady growth in the forecast period (2020-2027).

Troponin segment is expected to be the leading segment in this market during the forecast period.

Rising prevalence of cardiovascular diseases and introduction of POC cardiac biomarkers tests are some of the major factors anticipated to drive the market.

F. Hoffmann-La Roche AG, Abbott and Siemens AG., are some of the leading player in the global market.

North America dominated the market in 2019.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts
Speak to an Expert
  • REPORT UPDATE
    IN PROCESS
  • 2019-2032
    (In Process)
  • 2023
    (In Process)
Multi-report Purchase Plan
    A Customized Plan Will be Created Based on the number of reports you wish to purchase
Healthcare Clients
Lek
abbvie
Grifols
Amgen
Roche
Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X